Simple objective detection of human lyme disease infection using immuno-PCR and a single recombinant hybrid antigen

Clinical and Vaccine Immunology

Volumn 21, Issue 8, 2014, Pages 1094-1105

  Halpern, Micah D ^a   Molins, Claudia R ^b   Schriefer, Martin ^b   Jewett, Mollie W ^a  

^a UNIVERSITY OF CENTRAL FLORIDA COLLEGE OF MEDICINE   (United States)

^b NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; RECOMBINANT ANTIGEN; RECOMBINANT HYBRID ANTIGEN; UNCLASSIFIED DRUG; BACTERIAL ANTIGEN; BACTERIAL PROTEIN; BACTERIUM ANTIBODY; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; RECOMBINANT PROTEIN;

ANTIBODY DETECTION; ANTIBODY RESPONSE; ARTICLE; BORRELIA BURGDORFERI; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; FEASIBILITY STUDY; HUMAN; IMMUNO POLYMERASE CHAIN REACTION; INTERMETHOD COMPARISON; LYME DISEASE; MULTIPLEX POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; VALIDATION STUDY; BLOOD; CELL LINE; GENETICS; IMMUNOLOGY; POLYMERASE CHAIN REACTION; PROCEDURES;

ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; BORRELIA BURGDORFERI; CELL LINE; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LYME DISEASE; POLYMERASE CHAIN REACTION; RECOMBINANT PROTEINS; SENSITIVITY AND SPECIFICITY;

EID: 84906688940     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00245-14     Document Type: Article

References (42)

1. Bacon RM, Kugeler KJ, Mead PS, Centers for Disease Control and Prevention (CDC). 2008. Surveillance for Lyme disease - United States, 1992-2006. MMWR Surveill. Summ. 57:1-10.
2. Kuehn BM. 2013. CDC estimates 300,000 US cases of Lyme disease annually. JAMA 310:1110. http://dx.doi.org/10.1001/jama.2013.278331.
3. Campbell GL, Fritz CL, Fish D, Nowakowski J, Nadelman RB, Wormser GP. 1998. Estimation of the incidence of Lyme disease. Am. J. Epidemiol. 148:1018-1026. http://dx.doi.org/10.1093/oxfordjournals.aje.a009568. (Pubitemid 28533743)
4. Young JD. 1998. Underreporting of Lyme disease. N. Engl. J. Med. 338:1629. http://dx.doi.org/10.1056/NEJM199805283382216.
5. Aucott J, Morrison C, Munoz B, Rowe PC, Schwarzwalder A, West SK. 2009. Diagnostic challenges of early Lyme disease: lessons from a community case series. BMC Infect. Dis. 9:79. http://dx.doi.org/10.1186/1471-2334-9-79.
6. Centers for Disease Control and Prevention (CDC). 1995. Recommendations for test performance and interpretation from the Second National Conference on Serologic Diagnosis of Lyme Disease.MMWRMorb. Mortal. Wkly. Rep. 44:590-591.
7. Aguero-Rosenfeld ME, Wang G, Schwartz I, Wormser GP. 2005. Diagnosis of lyme borreliosis. Clin. Microbiol. Rev. 18:484-509. http://dx.doi.org/10.1128/ CMR.18.3.484-509.2005. (Pubitemid 40995113)
8. Wormser GP, Liveris D, Hanincová K, Brisson D, Ludin S, Stracuzzi VJ, Embers ME, Philipp MT, Levin A, Aguero-Rosenfeld M, Schwartz I. 2008. Effect of Borrelia burgdorferi genotype on the sensitivity of C6 and 2-tier testing in North American patients with culture-confirmed Lyme disease. Clin. Infect. Dis. 47:910-914. http://dx.doi.org/10.1086/591529.
9. Binnicker MJ, Jespersen DJ, Harring JA, Rollins LO, Bryant SC, Beito EM. 2008. Evaluation of two commercial systems for automated processing, reading, and interpretation of Lyme borreliosis Western blots. J. Clin. Microbiol. 46:2216-2221. http://dx.doi.org/10.1128/JCM.00200-08.
10. Halpern MD, Jain S, Jewett MW. 2013. Enhanced detection of host response antibodies to Borrelia burgdorferi using immuno-PCR. Clin. Vaccine Immunol. 20:350-357. http://dx.doi.org/10.1128/CVI.00630-12.
11. Sillanpää H, Lahdenne P, Sarvas H, Arnez M, Steere A, Peltomaa M, Seppälä I. 2007. Immune responses to borrelial VlsE IR6 peptide variants. Int. J. Med. Microbiol. 297:45-52. http://dx.doi.org/10.1016/j.ijmm. 2006.09.001. (Pubitemid 46149471)
12. Arnaboldi PM, Seedarnee R, Sambir M, Callister SM, Imparato JA, Dattwyler RJ. 2013. Outer surface protein C peptide derived from Borrelia burgdorferi sensu stricto as a target for serodiagnosis of early Lyme disease. Clin. Vaccine Immunol. 20:474-481. http://dx.doi.org/10.1128/CVI.00608-12.
13. Coburn J, Cugini C. 2003. Targeted mutation of the outer membrane protein P66 disrupts attachment of the Lyme disease agent, Borrelia burgdorferi, to integrin alphavbeta3. Proc. Natl. Acad. Sci. U. S. A. 100:7301-7306. http://dx.doi.org/10.1073/pnas.1131117100. (Pubitemid 36706433)
14. Seshu J, Esteve-Gassent MD, Labandeira-Rey M, Kim JH, Trzeciakowski JP, Höök M, Skare JT. 2006. Inactivation of the fibronectin-binding adhesin gene bbk32 significantly attenuates the infectivity potential of Borrelia burgdorferi. Mol. Microbiol. 59:1591-1601. http://dx.doi.org/10.1111/j. 1365-2958.2005.05042.x.
15. Brissette CA, Bykowski T, Cooley AE, Bowman A, Stevenson B. 2009. Borrelia burgdorferi RevA antigen binds host fibronectin. Infect. Immun. 77:2802-2812. http://dx.doi.org/10.1128/IAI.00227-09.
16. Guo BP, Norris SJ, Rosenberg LC, Höök M. 1995. Adherence of Borrelia burgdorferi to the proteoglycan decorin. Infect. Immun. 63:3467-3472.
17. Verma A, Brissette CA, Bowman A, Stevenson B. 2009. Borrelia burgdorferi BmpA is a laminin-binding protein. Infect. Immun. 77:4940-4946. http://dx.doi.org/10.1128/IAI.01420-08.
18. Kraiczy P, Stevenson B. 2013. Complement regulator-acquiring surface proteins of Borrelia burgdorferi: structure, function and regulation of gene expression. Ticks Tick Borne Dis. 4:26-34. http://dx.doi.org/10.1016/j.ttbdis. 2012.10.039.
19. Padula SJ, Dias F, Sampieri A, Craven RB, Ryan RW. 1994. Use of recombinant OspC from Borrelia burgdorferi for serodiagnosis of early Lyme disease. J. Clin. Microbiol. 32:1733-1738. (Pubitemid 24189566)
20. Simpson WJ, Schrumpf ME, Schwan TG. 1990. Reactivity of human Lyme borreliosis sera with a 39-kilodalton antigen specific to Borrelia burgdorferi. J. Clin. Microbiol. 28:1329-1337. (Pubitemid 20194427)
21. Barbour AG, Jasinskas A, Kayala MA, Davies DH, Steere AC, Baldi P, Felgner PL. 2008. A genome-wide proteome array reveals a limited set of immunogens in natural infections of humans and white-footed mice with Borrelia burgdorferi. Infect. Immun. 76:3374-3389. http://dx.doi.org/10.1128/IAI.00048- 08.
22. Panelius J, Lahdenne P, Saxén H, Carlsson SA, Heikkilä T, Peltomaa M, Lauhio A, Seppälä I. 2003. Diagnosis of Lyme neuroborreliosis with antibodies to recombinant proteins DbpA, BBK32, and OspC, and VlsE IR6 peptide. J. Neurol. 250:1318-1327. http://dx.doi.org/10.1007/ s00415-003-0205-2. (Pubitemid 37456892)
23. Krause A, Burmester GR, Rensing A, Schoerner C, Schaible UE, Simon MM, Herzer P, Kramer MD, Wallich R. 1992. Cellular immune reactivity to recombinant OspA and flagellin from Borrelia burgdorferi in patients with Lyme borreliosis. Complexity of humoral and cellular immune responses. J. Clin. Invest. 90:1077-1084.
24. Burbelo PD, Issa AT, Ching KH, Cohen JI, Iadarola MJ, Marques A. 2010. Rapid, simple, quantitative, and highly sensitive antibody detection for Lyme disease. Clin. Vaccine Immunol. 17:904-909. http://dx.doi.org/10.1128/CVI.00476- 09.
25. Fikrig E, Feng W, Barthold SW, Telford SR, III, Flavell RA. 2000. Arthropod- and host-specific Borrelia burgdorferi bbk32 expression and the inhibition of spirochete transmission. J. Immunol. 164:5344-5351. http://dx.doi.org/10.4049/jimmunol.164.10.5344. (Pubitemid 30305214)
26. Brissette CA, Rossmann E, Bowman A, Cooley AE, Riley SP, Hunfeld KP, Bechtel M, Kraiczy P, Stevenson B. 2010. The borrelial fibronectin-binding protein RevA is an early antigen of human Lyme disease. Clin. Vaccine Immunol. 17:274-280. http://dx.doi.org/10.1128/CVI.00437-09.
27. Kraiczy P, Skerka C, Brade V, Zipfel PF. 2001. Further characterization of complement regulator-acquiring surface proteins of Borrelia burgdorferi. Infect. Immun. 69:7800-7809. http://dx.doi.org/10.1128/IAI.69.12.7800-7809.2001. (Pubitemid 33086611)
28. Fischer A, von Eiff C, Kuczius T, Omoe K, Peters G, Becker K. 2007. A quantitative real-time immuno-PCR approach for detection of staphylococcal enterotoxins. J. Mol. Med. (Berl.) 85:461-469. http://dx.doi.org/10.1007/s00109- 006-0142-5. (Pubitemid 46701655)
29. Shan J, Toye P. 2009. A novel immuno-polymerase chain reaction protocol incorporating a highly purified streptavidin-DNA conjugate. J. Immunoassay Immunochem. 30:322-337. http://dx.doi.org/10.1080/15321810903084764.
30. Banin S, Wilson SM, Stanley CJ. 2004. Demonstration of an alternative approach to immuno-PCR. Clin. Chem. 50:1932-1934. http://dx.doi.org/10.1373/ clinchem.2004.037143.
31. McKie A, Samuel D, Cohen B, Saunders NA. 2002. Development of a quantitative immuno-PCR assay and its use to detect mumps-specific IgG in serum. J. Immunol. Methods 261:167-175. http://dx.doi.org/10.1016/S0022-1759(02)00003- 0. (Pubitemid 34175226)
32. Zhou H, Fisher RJ, Papas TS. 1993. Universal immuno-PCR for ultra-sensitive target protein detection. Nucleic Acids Res. 21:6038-6039. http://dx.doi.org/10.1093/nar/21.25.6038. (Pubitemid 24023724)
33. Barletta J, Bartolome A, Constantine NT. 2009. Immunomagnetic quantitative immuno-PCR for detection of less than one HIV-1 virion. J. Virol. Methods 157:122-132. http://dx.doi.org/10.1016/j.jviromet.2008.12.013.
34. Niemeyer CM, Adler M, Wacker R. 2007. Detecting antigens by quantitative immuno-PCR. Nat. Protoc. 2:1918-1930. http://dx.doi.org/10.1038/nprot.2007.267. (Pubitemid 47308130)
35. Karlen Y, McNair A, Perseguers S, Mazza C, Mermod N. 2007. Statistical significance of quantitative PCR. BMC Bioinformatics 8:131. http://dx.doi.org/ 10.1186/1471-2105-8-131.
36. FDA. 2001. Guidance for industry: bioanalytical method validation. U.S. Food and Drug Administration, Rockville, MD. http://www.fda.gov/downloads/Drugs/ Guidances/ucm070107.pdf.
37. Gomes-Solecki MJ, Wormser GP, Persing DH, Berger BW, Glass JD, Yang X, Dattwyler RJ. 2001. A first-tier rapid assay for the serodiagnosis of Borrelia burgdorferi infection. Arch. Intern. Med. 161:2015-2020. http://dx.doi.org/10. 1001/archinte.161.16.2015.
38. Gomes-Solecki MJ, Dunn JJ, Luft BJ, Castillo J, Dykhuizen DE, Yang X, Glass JD, Dattwyler RJ. 2000. Recombinant chimeric Borrelia proteins for diagnosis of Lyme disease. J. Clin. Microbiol. 38:2530-2535. (Pubitemid 30485124)
39. Mathiesen MJ, Christiansen M, Hansen K, Holm A, Asbrink E, Theisen M. 1998. Peptide-based OspC enzyme-linked immunosorbent assay for serodiagnosis of Lyme borreliosis. J. Clin. Microbiol. 36:3474-3479. (Pubitemid 28533213)
40. Liang FT, Alvarez AL, Gu Y, Nowling JM, Ramamoorthy R, Philipp MT. 1999. An immunodominant conserved region within the variable domain of VlsE, the variable surface antigen of Borrelia burgdorferi. J. Immunol. 163:5566-5573.
41. Glatz M, Fingerle V, Wilske B, Ambros-Rudolph C, Kerl H, Müllegger RR. 2008. Immunoblot analysis of the seroreactivity to recombinant Borrelia burgdorferi sensu lato antigens, including VlsE, in the long-term course of treated patients with erythema migrans. Dermatology 216:93-103. http://dx.doi.org/10.1159/000111505. (Pubitemid 351158572)
42. Schulte-Spechtel U, Fingerle V, Goettner G, Rogge S, Wilske B. 2006. Molecular analysis of decorin-binding protein A (DbpA) reveals five major groups among European Borrelia burgdorferi sensu lato strains with impact for the development of serological assays and indicates lateral gene transfer of the dbpA gene. Int. J. Med. Microbiol. 296(Suppl 40):S250-S266. http://dx.doi.org/ 10.1016/j.ijmm.2006.01.006.